mgc018
mAbexperimentalADC
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Nov 21, 2018 (NCT03729596)
Timeline
Indications
Studied for
- Anus Neoplasms · Phase 2/Phase 3
- Carcinoma, Non-Small-Cell Lung · Phase 2/Phase 3
- Carcinoma, Ovarian Epithelial · Phase 1
- Carcinoma, Pancreatic Ductal · Phase 1
- Carcinoma, Renal Cell · Phase 1
- Carcinoma, Small Cell · Phase 2/Phase 3
- Liver Neoplasms · Phase 1
- Melanoma · Phase 2/Phase 3
- Neoplasms · Phase 1/Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 2/Phase 3
- Small Cell Lung Carcinoma · Phase 2/Phase 3
- Squamous Cell Carcinoma of Head and Neck · Phase 2/Phase 3
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
Mechanism of action
- CD276 antigenINHIBITOR
CD276 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- duocarmycin
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594576 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06227546 | Phase 2 | Apr 15, 2024 | Georgetown University, MacroGenics |
| NCT05551117 | Phase 2/Phase 3 (Phase 3) | Nov 30, 2022 | MacroGenics |
| NCT05293496 | Phase 1 | Apr 19, 2022 | MacroGenics |
| NCT03729596 | Phase 1/Phase 2 (Phase 2) | Nov 21, 2018 | MacroGenics |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MacroGenics | For profit | 4 | 3 | 3 | 2018 |
| Georgetown University | Academic/Hospital | 1 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1